## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($252.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. TKO Group Lifts Quarterly Dividend to $0.78 per Class A Share, Payable Dec. 30 to Holders of Record as of Dec. 15**
- Source: MarketScreener | 20251204T140858 | Somewhat-Bullish | Relevance: 71%
- TKO Group Holdings, Inc. has announced an increase in its quarterly dividend to $0.78 per Class A share. This dividend is payable on December 30, 2025, to shareholders of record as of December 15, 2025. The announcement was made on December 4, 2025, at 08:49 am EST.

**2. UnitedHealth Group (UNH) Stock Today: Price, Forecast and 2026 Recovery Prospects (December 2, 2025)**
- Source: ts2.tech | 20251202T160454 | Neutral | Relevance: 68%
- UnitedHealth Group (UNH) stock is trading around $325-326 on December 2, 2025, significantly below its 52-week high but with Wall Street maintaining a "Buy" consensus and double-digit upside potential for 2026. The article discusses a turbulent 2025 for UNH, marked by an earnings miss, regulatory scrutiny, a cyberattack, and strategic shifts like exiting Latin America, while also highlighting a Q3 beat and revised 2025 EPS guidance, positioning UNH as a high-risk, high-reward turnaround story for investors. Despite ongoing regulatory, reputational, and medical cost risks, analysts see UNH as potentially undervalued, with a long-term earnings growth target of 13-16% and a 2.7% dividend yield, making it a "battleground stock" for risk-tolerant investors.

**3. Investors Pack Into CVS Ahead Of Make-Or-Break Update**
- Source: Finimize | 20251203T165133 | Neutral | Relevance: 61%
- CVS Health is approaching a critical investor day, with UBS noting the stock is "long crowded and well liked" due to anticipation of a multi-year recovery. The market is focused on margin recovery in its Health Care Benefits, how Caremark handles contract renewals, and the stabilization of the Pharmacy and Consumer Wellness business. While UBS anticipates conservative guidance, any disappointment could lead to a sell-off, whereas modest positive news could reinforce confidence in CVS's turnaround.

**4. Listening to healthcare professionals: Dexcom launches new education offering, Dexcom Academy**
- Source: MarketScreener | 20251204T131053 | Somewhat-Bullish | Relevance: 60%
- Dexcom, Inc. has announced the launch of Dexcom Academy, a new educational offering designed for healthcare professionals. This initiative reflects Dexcom's commitment to continuous glucose monitoring (CGM) education, responding to feedback from medical practitioners. The academy aims to enhance understanding and implementation of CGM technology in diabetes management.

**5. Chubb (CB) survey: 79% wealthy see growth as 74% still lack estate plans in 2025**
- Source: Stock Titan | 20251203T140000 | Somewhat-Bullish | Relevance: 57%
- Chubb's 2025 wealth survey, "The Resilient Mindset," reveals high optimism among affluent North Americans (79% expect economic growth), yet significant protection gaps exist. A striking 74% lack an estate plan and cyber risk is the top concern, despite only 41% having standalone cyber insurance. The survey also highlights trends in luxury spending, collectibles, and concerns about extreme weather and marine liability, emphasizing the generational wealth transfer complexities.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 5)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-12 | Bernstein | $294 | $346 | -15% |
| 2025-11-05 | Wells Fargo | $300 | $354 | -15% |
| 2025-11-04 | TD Cowen | $333 | $387 | -14% |
| 2025-11-04 | Goldman Sachs | $330 | $370 | -11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-12 | Bernstein | main | Market Perform |
| 2025-11-05 | Wells Fargo | main | Equal-Weight |
| 2025-11-04 | TD Cowen | main | Buy |
| 2025-11-04 | Goldman Sachs | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 11.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.56 indicates undervaluation relative to growth. Forward P/E 8.8x stretched relative to 3% growth. Balance sheet: $3.1B free cash flow. Analyst sentiment negative (5 target cuts vs 0 raises). Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $73.9B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.56 |
| Forward P/E | 8.8 |
| Current P/E | 9.1 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.5% to -3.5% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.5pp (needs >3.0% for momentum thesis). Below SMA200 (0.88x), long-term trend not supportive. MACD histogram positive (0.76), confirming momentum. RSI neutral at 44. OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.48% (CS: 15) | Weak |
| RSI_14 | 43.6 | Neutral |
| MACD Histogram | 0.76 | Bullish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 0.946x | Below |
| vs SMA200 | 0.883x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $268.42
- **Stop Loss:** $252.88 (5.8% risk)
- **Target:** $283.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 32
- **Position Value:** $8,589.44
- **Portfolio %:** 8.59%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*